Skip to content
Dose Brief
Menu
No. 252 here · Grade C

Pallas Health review

A new provider that names six dispensing pharmacies and two NPI-verified prescribers — wrapped around a "$199/mo average" no monthly plan sells, because the bill is $597 every 12 weeks and 12 weeks is not three months.

Visit Pallas Health Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.
Semaglutide
$199/mo average, compounded — but it bills $597 every 12 weeks, not monthly ($139 first 4 weeks)
Tirzepatide
$299/mo average, compounded — but it bills $897 every 12 weeks, not monthly ($179 first 4 weeks)
Coverage
Nationwide — all 50 states + DC
Brand-name
Yes

Prices read from Pallas Health's own site on . Providers change pricing without notice — check the current figure before you buy.

On the trackerNewnew to the tracker, no prior reading— First reading, 7 August 2026. The advertised averages are $199/mo semaglutide and $299/mo tirzepatide, but no month-to-month plan exists to buy: the charge is $139 up front, then $597 every 12 weeks from four weeks after approval ($179, then $897, on tirzepatide). Because an 84-day cycle recurs 4.35 times a year rather than four, those renewal terms work out at roughly $216 and $325 a month once the intro period is behind you.

The scorecard

Pallas Health scored on our six Brief Score factors. See the methodology.

Price Stability50/100
Supply Reliability82/100
Transparency58/100
Access Breadth66/100
Clinical Oversight78/100
Track Record44/100

Pallas Health in depth

Pallas Health advertises semaglutide at "$199/mo average" and tirzepatide at "$299/mo average", and the word doing the work in both is average. There is no monthly plan here. The funnel offers no cadence to choose, and the renewal is anchored, in the company's own words, "every 12 weeks starting 4 weeks after approval".

What that means in practice is a sequence rather than a monthly bill. On semaglutide you pay $139 now, then $597 four weeks later, then $597 every twelve weeks after that. On tirzepatide it is $179, then $897, then $897. The second charge is the one to plan for: it is the full amount, in one go, four weeks after a much smaller first payment.

There is also a divisor worth checking. Twelve weeks is not three months — an 84-day cycle comes round about 4.35 times a year rather than four. On Pallas's own published renewal terms that works out at roughly $216 a month for semaglutide in steady state and about $325 for tirzepatide, against advertised averages of $199 and $299. Treating twelve weeks as three months is ordinary shorthand across this industry; we show the arithmetic and leave it there.

On disclosure, Pallas is among the strongest in this ranking, and that is not a throwaway compliment. It names six dispensing pharmacies outright and explains the 503A/503B distinction. It names two prescribing physicians with NPI numbers and puts a "verify in the NPPES registry" link beside them; both check out as active. And the price it markets is the price at checkout on every surface we looked at.

One precision about the clinical claims: the federal registry confirms Dr Carr's family-medicine taxonomy, but the obesity- and addiction-medicine board certifications the site also claims for her are not verifiable there and we did not confirm them elsewhere. Pallas itself is clean against the FDA warning-letter index, screened August 7, 2026 with a passing positive control.

What we like

  • Names SIX dispensing pharmacies outright — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — and explains the 503A/503B distinction, where almost nothing else in this ranking names one
  • Names two prescribing physicians with their NPI numbers and links the federal registry to check them: Dr. Ana Lisa Carr (NPI 1689841744, family medicine, NPI-verified, licensed in 15 states) and Dr. Kelly Tenbrink (NPI 1346482684, emergency medicine, Tennessee and Florida). Both verify as active.
  • The advertised price is the checkout price: the same four figures appear in the homepage FAQ, on the landing and treatment pages and in the live funnel, with no step-up at the payment screen
  • Reaches all 50 states and DC, fully asynchronously in 43 of them, and sells brand Zepbound, Ozempic, Wegovy and Mounjaro cash-pay alongside the compounded lines
  • No minimum term. Cancellation is self-serve through its own portal and takes effect at the end of the current billing period, a reminder email goes out before each renewal, and any price increase requires 30 days' notice
  • Clean against FDA's warning-letter index under the brand, the domain, the operating company and its clinical platform, screened 7 August 2026 with a passing positive control

The caveats

  • There is no month-to-month plan to buy. The "$199/mo average" is a $597 charge every 12 weeks divided by three, and the funnel offers no monthly cadence instead — after a $139 first payment, the second charge is the full $597, in one go, four weeks later ($179 then $897 on tirzepatide)
  • 12 weeks is not three months. An 84-day cycle recurs 4.35 times a year rather than four, so their own published renewal terms work out at about $216 a month on semaglutide and about $325 on tirzepatide, against advertised averages of $199 and $299
  • Pallas itself carries no FDA warning letter, but one of the six pharmacies it names does: Belmar received one issued March 2023, addressed to Belmar Pharma Solutions, Drug Depot, LLC. dba APS Pharmacy, and FDA closed it out in October 2023. Disclosed because the pharmacy is named — a closed-out letter on a dispensing partner is a fact to weigh, not a disqualification.
  • $139 and $179 are first-period rates only, and the sitewide "Up to $120 off your first month" banner is a discount, not a price
  • A $60 visit deposit may be kept if you skip or fail to reschedule the video visit required in Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and DC, then abandon the intake; otherwise it is refunded in full and credited to the first order. Separately, a $5 fee is deducted from each refunded payment on purchases made on or after 14 July 2026 — never on clinician-declined or unfulfilled orders, which refund in full.
  • Only two clinicians are named site-wide, and the footer's "Provider directory" link resolves to that same pair. The affiliated professional corporations that actually prescribe are not published, and Pallas states plainly that it is a technology platform which does not employ medical providers.
  • The advertised "4.8" rating cites no source, the before-and-after "Verified Customer" stories carry an "individuals shown may be actors or models" caveat, and the site's own footer states that some of its content is AI-generated with no warranty as to accuracy — so its blog is not a source for a clinical claim
  • Compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents of Wegovy or Zepbound, which Pallas discloses properly. Cash-pay only, no insurance ever, and the brand-name lines run $1,069–$1,349/mo — far above what an insured patient pays.
  • Whether baseline or follow-up lab work is included or billed separately is not published, and neither is whether the price rises with dose beyond the flat claim — there is no pre-purchase dose selector. No Trustpilot or BBB record is published either.

The brief

Best for: Readers who can absorb $597 in a single charge every 12 weeks and want a provider that will tell them who compounds and who prescribes — not readers budgeting a predictable monthly bill. A new provider that names six dispensing pharmacies and two NPI-verified prescribers — wrapped around a "$199/mo average" no monthly plan sells, because the bill is $597 every 12 weeks and 12 weeks is not three months.

Ranked #252 of 546 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Visit Pallas Health

Before you decide

The questions readers ask next after reading about Pallas Health.

Closest here

The providers scoring nearest Pallas Health — the realistic shortlist if you're weighing it.

Weighing Pallas Health against one provider in particular? There is a full head-to-head with our top-ranked pick in CoreAge Rx vs Pallas Health, and every provider that outranks it is listed on the Pallas Health alternatives ranking.

More providers we track (24)

515 more are filed too — see every provider we track, ranked.

Pricing, states and verification reflect Pallas Health's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Pallas Health's site. Not medical advice; see our disclosure.

← Back to all rankings